一个基于生物标志物的剂量计划优化设计,用于免疫疗法试验
Yingjie Qiu1,2, Yan Han3, Beibei Guo4
1Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Statistics in medicine
|January 23, 2026
概括
优化免疫治疗药物剂量和时间表至关重要. 这项研究提出了一个定制的策略,使用免疫反应,疗效和毒性数据用于生物标记子组,改善临床试验决策.
科学领域:
- 免疫治疗是一种免疫疗法.
- 临床试验设计 临床试验设计
- 生物统计学 生物统计学
背景情况:
- 药物剂量和时间表通过调节免疫反应显著影响免疫疗法的有效性.
- 将免疫反应措施纳入临床试验有助于决策,因为它们与疗效和毒性有关.
- 生物标志物数据可以识别改善治疗疗效的患者子组.
研究的目的:
- 为免疫治疗临床试验制定剂量-时间表优化策略.
- 根据特定的生物标志物定义的患者子组量身定制治疗优化.
- 利用免疫反应,毒性和疗效数据来加强决策.
主要方法:
- 开发了一个联合建模框架,同时评估免疫反应,毒性和疗效.
- 效用函数被引发,以捕捉患者特定的风险-收益权衡.
- 在早期试验中,节但灵活的模型被用于处理小样本大小.
主要成果:
- 拟议的联合建模框架使不同结果类型和患者子组的信息共享成为可能.
- 模拟研究表明,对于剂量-时间表优化设计,可望的操作特性.
- 这种方法有效地告知了量身定制为生物标志物子组的剂量表优化.
结论:
- 一种新的剂量-时间表优化策略提高了免疫疗法临床试验设计.
- 根据生物标志物子组和综合结果建模量身定制治疗,可以改善风险效益评估.
- 提出的方法适用于早期阶段的试验,样本规模有限.
关键词:
贝叶斯适应式设计是贝叶斯的适应式设计.生物标志物生物标志物免疫疗法 免疫疗法最佳的治疗方案是最佳的治疗方案.第I/II阶段试验试验风险/收益权衡权衡权衡权衡权衡权衡权衡权衡权衡这些子组是分组.更多相关视频
相关概念视频
01:24Reinforcement Schedules
479
Positive reinforcement is a powerful method for teaching new behaviors to both animals and humans. B.F. Skinner demonstrated this with his experiments using rats in a Skinner box. When a rat pressed a lever, it received a food pellet. This immediate reward encouraged the rat to repeat the behavior. This method, where a reward follows every instance of the behavior, is known as continuous reinforcement. It is highly effective for establishing new behaviors quickly.
Once a behavior is learned,...
Once a behavior is learned,...
479
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
220
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
220
01:27Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
217
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
217
01:16Clinical Trials
10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.2K
01:11Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K